Recent News

• 11.13.2025 - Monopar Therapeutics Reports Third Quarter 2025 Financial Results and Recent Developments
• 11.13.2025 - Monopar Therapeutics Reports Third Quarter 2025 Financial Results and Recent Developments
• 11.09.2025 - Monopar Presents New Data and Analyses on Rapidly Improved Copper Balance in Wilson Disease Patients on Tiomolybdate Choline at AASLD - The Liver Meeting® 2025
• 11.09.2025 - Monopar Presents New Data and Analyses on Rapidly Improved Copper Balance in Wilson Disease Patients on Tiomolybdate Choline at AASLD - The Liver Meeting® 2025
• 10.15.2025 - Monopar Announces Abstract Accepted for Oral Presentation at AASLD - The Liver Meeting® 2025
• 10.15.2025 - Monopar Announces Abstract Accepted for Oral Presentation at AASLD - The Liver Meeting® 2025
• 09.24.2025 - Monopar Therapeutics Inc. Announces Pricing of $135 Million Underwritten Offering of Common Stock and Pre-Funded Warrants
• 09.24.2025 - Monopar Therapeutics Inc. Announces Pricing of $135 Million Underwritten Offering of Common Stock and Pre-Funded Warrants
• 09.24.2025 - Monopar Announces Journal of Hepatology Publishes Physicians’ Letter to the Editor Demonstrating ALXN1840 Rapidly Improved Copper Balance in Wilson Disease Patients
• 09.24.2025 - Monopar Announces Journal of Hepatology Publishes Physicians’ Letter to the Editor Demonstrating ALXN1840 Rapidly Improved Copper Balance in Wilson Disease Patients

Recent Filings

• 11.13.2025 - 10-Q Quarterly report [Sections 13 or 15(d)]
• 11.13.2025 - EX-99.1 EX-99.1
• 11.13.2025 - 8-K Current report
• 11.10.2025 - 8-K Current report
• 11.10.2025 - EX-99.1 EX-99.1
• 10.02.2025 - 4 Statement of changes in beneficial ownership of securities
• 10.02.2025 - 4 Statement of changes in beneficial ownership of securities
• 09.26.2025 - 4 Statement of changes in beneficial ownership of securities
• 09.24.2025 - EX-99.1 EX-99.1
• 09.24.2025 - 8-K Current report